Literature DB >> 31258039

On the relative efficiency of model-assisted designs: a conditional approach.

Ruitao Lin1, Ying Yuan1.   

Abstract

In phase I dose-finding trials, model-assisted designs are a novel class of designs that combine the simplicity of algorithm-based methods with the superior performance of model-based methods. Examples of model-assisted designs include the modified toxicity probability (mTPI), Bayesian optimal interval (BOIN) and keyboard designs. To achieve simplicity, these model-assisted methods model only "local" data observed at the current dose, typically using a binomial model, to guide dose assignments. This potentially causes efficiency loss, however, by ignoring the data observed in other doses. To investigate this issue, we propose a conditional approach that utilizes the data from both current and adjacent (i.e., next higher or lower) doses to make the dose-assignment decisions. Specifically, we propose the conditional optimal interval (COIN) design, as the conditional approach extension of the BOIN design. We investigate the theoretical properties of the COIN design and conduct extensive numerical studies to examine its performance in comparison with existing model-assisted designs. We also present the conditional approach to the keyboard design. We observe that the conditional approach improves patient allocation, but yields similar maximum-tolerated dose (MTD) identification accuracy as the model-assisted designs, suggesting only minor efficiency loss using local data under the model-assisted designs.

Entities:  

Keywords:  Adaptive designs; dose finding; maximum tolerated dose; model-assisted designs; phase I trial

Year:  2019        PMID: 31258039      PMCID: PMC6733273          DOI: 10.1080/10543406.2019.1632881

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  16 in total

Review 1.  The changing landscape of phase I trials in oncology.

Authors:  Kit Man Wong; Anna Capasso; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2015-11-10       Impact factor: 66.675

2.  Critical aspects of the Bayesian approach to phase I cancer trials.

Authors:  Beat Neuenschwander; Michael Branson; Thomas Gsponer
Journal:  Stat Med       Date:  2008-06-15       Impact factor: 2.373

3.  Bayesian optimal interval design for dose finding in drug-combination trials.

Authors:  Ruitao Lin; Guosheng Yin
Journal:  Stat Methods Med Res       Date:  2015-07-15       Impact factor: 3.021

4.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

5.  Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.

Authors:  Ying Yuan; Kenneth R Hess; Susan G Hilsenbeck; Mark R Gilbert
Journal:  Clin Cancer Res       Date:  2016-07-12       Impact factor: 12.531

6.  A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.

Authors:  Liangcai Zhang; Ying Yuan
Journal:  Stat Med       Date:  2016-08-31       Impact factor: 2.373

7.  Design and analysis of phase I clinical trials.

Authors:  B E Storer
Journal:  Biometrics       Date:  1989-09       Impact factor: 2.571

8.  Up-and-down designs for phase I clinical trials.

Authors:  Suyu Liu; Chunyan Cai; Jing Ning
Journal:  Contemp Clin Trials       Date:  2013-07-13       Impact factor: 2.226

9.  A modified toxicity probability interval method for dose-finding trials.

Authors:  Yuan Ji; Ping Liu; Yisheng Li; B Nebiyou Bekele
Journal:  Clin Trials       Date:  2010-10-08       Impact factor: 2.486

10.  Small-sample behavior of novel phase I cancer trial designs.

Authors:  Assaf P Oron; Peter D Hoff
Journal:  Clin Trials       Date:  2013-02       Impact factor: 2.486

View more
  1 in total

Review 1.  An overview of the BOIN design and its current extensions for novel early-phase oncology trials.

Authors:  Revathi Ananthakrishnan; Ruitao Lin; Chunsheng He; Yanping Chen; Daniel Li; Michael LaValley
Journal:  Contemp Clin Trials Commun       Date:  2022-06-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.